Nasus Pharma Ltd (NSRX) stock

NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026Score 6/30

$2.87+0.05 (+1.77%)

Close on Nov 13, 2026Market cap $25.87MP/E –Yield –

Nasus Pharma enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Nasus Pharma's enterprise value was $15.49M on Nov 11, 2026, against $51.34M a year earlier.

Period	Period end	Value	Change
2026	Nov 11, 2026	$15.49M	-76.9%
2025	Dec 31, 2025	$67.17M	–

Parsed from the XBRL in Nasus Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NSRX.

Operating margin-0.4% · median 10.2%

Net margin-0.5% · median 11.6%

Advertisement
300 × 250

See a number that looks wrong?